Good morning and welcome to Sleep Cycle's third quarter earnings call. I am Mikael Kågebäck, acting CEO and CTO. And I am joined today by Elisabeth Hedman, our CFO and Head of Investor Relations. Q3 was a quarter of record B2B revenue, a leaner organization, and we have proposed to acquire Audiowell, which shareholders will vote on at the AGM on the 11th of November.
Agenda.
Today I will take you through who we are and where we stand today. We will discuss the Audiowell proposal, and Elisabeth will then take us through the financials. Finally, we will conclude with a summary and take your questions.
Though we live in a time of change, I think we all can agree our purpose here remains as relevant as ever. We want to help people improve global health by helping them take control of their sleep. Sleep Cycle is in a unique position that is very hard to replicate for a newcomer. We have now analyzed over 4 billion nights of sleep. We have been installed over 82 million times around the world, and we have about 2.5 million yearly active users enjoying our world-leading sleep tracking. Our sticky smart alarm and our scientifically based sleep programs. And this has all been built largely through organic growth. That data, that distribution, and more than a decade of sleep expertise are exactly what every part of our strategy builds on, because sleep is much bigger than the sleep app category. It has been increasingly recognized as a driver of health recovery, performance, and longevity, and too little sleep is linked to obesity, diabetes, and cardiovascular disease. And due to this, sleep experiences are now moving into all kinds of things: wearables, pharma, digital health, smart home, and broader health platforms. And due to this, demand is growing for passive, continuous health insights built into products people already use.
And that is exactly where our technology is strongest.
Sleep Cycle consists of three pillars. We have Sleep Cycle AB, 1.4 million monthly active users and around 605,000 paying subscribers. We have Apnea Alert, a contactless sleep apnea risk detector planned to launch in the EU and UK in early 2027 under MDR Class I, and already more than 150,000 people have registered interest. And finally, we have tech licensing that provides sleep tracking for partners, apps, and hardware. And it's the fastest growing part of Sleep Cycle right now, representing 20% of our total revenue. But underneath all of these three pillars is the same shared technology platform powered by our patented sound-based AI model, trained on a massive proprietary data set and needing nothing more than a microphone. No ring, no watch. Just your phone. Next, I want to give you the current status of our pillars, starting with the Sleep Cycle app. We are now seeing the effects of our price increases with 2% improved ARPU on renewals. They remain stable, which highlights the strong stickiness in our product. However, new sales remain weak, with a 24% decrease in paying subscribers year-over-year, mainly due to falling organic traffic. Our focus going forward is to bend that curve, and we want to do that by introducing a new customer onboarding process that demonstrates value early to the customer coming in. We optimize the paywalls and offer new win-back offers, and we are closely collaborating with Apple to ensure good experiences on the new iOS devices now being launched.
Next up, Apnea Alert. Now with Apnea Alert, I think we are doing something very special. We are bringing low-friction, contactless sleep apnea risk detection to the masses. Our goal here is to make it as easy as downloading an app. So if you are worried that you suffer from sleep apnea, all you need is your phone and one night of sleep, and in the morning, you will know. But why is this so important? An estimated 1 billion people have sleep apnea worldwide, and around 80% of those are undiagnosed. They suffer from several effects, including excessive daytime fatigue, impaired memory, lack of concentration, and reduced cognitive performance. And they have an increased risk of cardiovascular disease and type 2 diabetes. We estimate that the total addressable market for this is around 25 billion USD. Seeking diagnosis today relies on sleep labs with referrals, overnight sensors, and long waiting lists, or it relies on wearables, which only reach people who already own and wear the device when they sleep. The effect of this is that those 80% remain undiagnosed. Most cases are never found. Apnea Alert needs one night with an iPhone on your bedside table, and we aim to reach people who have never been tested today. The launch plan is early next year. We will launch in the EU and the UK under MDR Class I, and the next step is going to be MDR Class IIa in the EU and FDA submission for the US. Finally, the third pillar is tech licensing. We will license our sleep analysis as an SDK so that our partners can build contactless sleep and breathing measurements into their own apps, devices, and hardware. It only needs a microphone and is built on the same patented technology we use in our app and in Apnea Alert. We have added partners in four different segments in wearables. Ultrahuman converted its pilot into a commercial SDK license in digital health. We signed the Ant Group, our entry into China, and in smart home, Moera launched its mattress with our analysis running directly on their hardware without a phone. Finally, we are doing things in public health as well. We finalized a joint research program with the UKHSA, the UK Health Security Agency, and it showed that our cough data can provide an early warning detection system to identify flu and COVID-19 waves in the UK. And we are now discussing a commercial pilot with the UKHSA. Taking all of this together, this progress is exactly why we have seen record numbers in our B2B business area this quarter. That brings me to the organization. In September, we introduced a more AI-driven way of working with fewer decision levels and smaller teams that own their own results. Three things have truly changed. We are now AI-first, completely AI-first. We build it into how we develop, how we analyze, and how we operate the business. And the roles have become broader. So very small teams, sometimes one person can own their own results end-to-end, which eliminates costly handovers between individuals. Finally, decisions are much faster because there are fewer levels between the decision and the work being done, and we have realized significant gains.
Well, we have annual savings of around 35 million SEK, with large effect already in the fourth quarter. But I think even more importantly, we are already seeing very good results and a higher pace in getting development into the hands of our users.
We are slimmer, more focused, and we have a clearer path to profitable growth.
And that makes us ready for the next chapter.
The proposed acquisition of Audiowell is an independent record label and music publisher for sleep and relaxation music, founded in Stockholm in 2013.
The idea behind the acquisition is quite simple: Sleep Cycle's sleep analysis and user base. Combined with Audiowell’s music catalogue, it widens our offer from sleep to wellbeing. It adds additional revenue streams in apps and streaming, and in white-label solutions, and with clear synergies between music streaming and Sleep Cycle's popular sleep aid feature. And as a group, it lets us tailor content to each user and launch faster. To give you an idea of the size of the combined business, the 2025 numbers are going to be 625 million SEK in net sales. It was 282 million in EBIT and a 45% profit margin. The acquisition will be paid in Sleep Cycle AB shares. Shareholders will vote at the EGM on the 11th of November, and we expect closing in the fourth quarter. If the deal goes through, Audiowell CEO Gustav Forssell is intended as CEO of the group, and I will take the role of CTO in the new group. With that, I hand over to Elisabeth.